Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia

Leukemia volume 19, page 135 (2005)Cite this article

Access through your institution
Buy or subscribe

TO THE EDITOR

Dr Laporte and colleagues recently described in Leukemia (September 2004, Vol 18, No. 9) an adult acute lymphoid leukemia (ALL) patients early relapsed after standard chemotherapy, and treated with alemtuzumab (campath 1H, Mab Campath, Schering AG, Germany).1 Alemtuzumab was administered at a dose of 30 mg, 3 days a week for 4 weeks, and then at a dose of 30 mg, 3 days a week every 2 months as maintenance, in association with G-CSF and erythropoietin (EPO). Notably, the patient achieved a long-lasting cytogenetic complete remission (CR), although without a complete recovery of the peripheral blood counts.1

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Laporte JP, Isnard F, Garderet L, Fouillard L, Gorin NC . Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia 2004; 18: 1557–1558.

    Article  CAS  Google Scholar 

  2. Piccaluga PP, Martinelli G, Malagola M, Rondoni M, Bianchini M, Vigna E et al. Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. Leukemia Lymphoma 2004; 45: 731–733.

    Article  CAS  Google Scholar 

  3. Dyer MJ, Hale G, Hayhoe FG, Waldmann H . Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431–1439.

    CAS  PubMed  Google Scholar 

  4. Thieblemont C, Bouafia F, Hornez E, Dumontet C, Tartas S, Antal D et al. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leukemia Lymphoma 2004; 45: 711–714.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by AIRC, AIL Bologna and Pesaro ONLUS, COFIN 2002 and 2003 (M Baccarani), Ateneo 2001 and 2002 grants. PPP is also supported by an American–Italian Cancer Foundation Fellowship.

Author information

Authors and Affiliations

  1. Institute of Haematology and Medical Oncology ‘L. & A. Seràgnoli’, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

    P P Piccaluga, G Martinelli, M Malagola, M Rondoni, F Bonifazi, G Bandini & M Baccarani

  2. Department of Hematology, S. Salvatore Hospital, Pesaro, Italy

    G Visani

Authors
  1. P P Piccaluga
    View author publications

    Search author on:PubMed Google Scholar

  2. G Martinelli
    View author publications

    Search author on:PubMed Google Scholar

  3. M Malagola
    View author publications

    Search author on:PubMed Google Scholar

  4. M Rondoni
    View author publications

    Search author on:PubMed Google Scholar

  5. F Bonifazi
    View author publications

    Search author on:PubMed Google Scholar

  6. G Bandini
    View author publications

    Search author on:PubMed Google Scholar

  7. G Visani
    View author publications

    Search author on:PubMed Google Scholar

  8. M Baccarani
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to P P Piccaluga.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piccaluga, P., Martinelli, G., Malagola, M. et al. Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. Leukemia 19, 135 (2005). https://doi.org/10.1038/sj.leu.2403578

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.leu.2403578

This article is cited by

Search

Advanced search

Quick links